Janux Therapeutics

Janux shares triple on early cancer immunotherapy data
BioPharma Dive
Wed, 02/28/24 - 11:08 am
Janux Therapeutics
clinical trials
solid tumors
prostate cancer
T-cell engager
Why Janux Therapeutics Shares Rose 33.1% This Week
Motley Fool
Sun, 10/23/22 - 06:56 pm
Janux Therapeutics
oncology
JANX007
clinical trials
metastatic castration-resistant prostate cancer
Janux doses first subject in Phase I prostate cancer therapy trial
Clinical Trials Arena
Thu, 10/13/22 - 09:43 am
Janux Therapeutics
JANX007
prostate cancer
clinical trials
Merck-partnered Janux hires CMO as its bispecifics near clinic
Fierce Biotech
Fri, 06/4/21 - 10:42 am
Janux Therapeutics
Merck
bispecifics
Stealthy biotech Janux nabs $125M and joins chase to direct T cells to solid tumors
MedCity News
Wed, 04/21/21 - 11:19 pm
Janux Therapeutics
R&D
solid tumors
Janux raises $56M to take safer T-cell engagers into the clinic
Fierce Biotech
Thu, 03/4/21 - 09:54 am
Janux Therapeutics
T-cell engager
Janux pairs up with Merck for $1B-plus T-cell engager deal
Fierce Biotech
Fri, 12/18/20 - 11:04 am
Merck
Janux Therapeutics
R&D
T-cell engager
cancer